Spyre Therapeutics Inc (SYRE)

$75.04 -1.39 (-1.82%)
Market Cap 6.64B
Revenue (ttm) 0.00
Net Income (ttm) -155.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,760,500
Avg Vol 1,148,886
Day's Range N/A - N/A
Shares Out 86.84M
Stochastic %K 68%
Beta 3.12
Analysts Strong Sell
Price Target $94.13

Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necros...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 651 5940
Address:
Building 23, Suite 105 221 Crescent Street, Waltham, United States
oaksapollo
oaksapollo May. 12 at 3:46 AM
$SYRE this is the most absurd valuation in biotech right now. Anyone can use YTE and do what they’re doing.
1 · Reply
chking09
chking09 May. 11 at 5:28 PM
$SYRE breakout?
0 · Reply
Quantumup
Quantumup May. 6 at 11:12 AM
Stifel y'day⬆️ $SYRE's PT to $107 (was $92), reit'd at Buy/said: Following best-in-class UC PoC data for SPY001 (α4β7), SYRE is well-positioned heading into additional PoC cohorts for SPY002 (TL1A) and SPY003 (IL-23p19) in mid-year/3Q26. $JNJ TAK APGE ABVX $ABBV Here's what else Stifel had to say: https://x.com/Quantumup1/status/2051982840607215753?s=20
0 · Reply
d_risk
d_risk May. 5 at 2:55 PM
$SYRE - Spyre Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +208.0% above peer average (36,855 vs 11,964 across 652 peers). SYRE’s 10-Q sharpens its downside: survival now explicitly hinges on new capital despite a large cash balance; it doubles down on going-concern, perpetual-loss, and no-revenue risks; concentrates dependence on four core programs and complex drug/device, biologics and CMC hurdles; and materially expands regulatory, IP, manufacturing, AI, talent, pricing, geopolitical and control‑weakness risks that could dilute shareholders, delay approvals and cripple commercialization. 🟢 Added 🟠 Removed https://d-risk.ai/SYRE/10-Q/2026-05-05
0 · Reply
Merlintrader
Merlintrader Apr. 30 at 11:10 PM
$SYRE Spyre Therapeutics 2026 (Nasdaq: $SYRE): When Great Clinical Data Matter More Than Promises https://www.merlintrader.com/spyre-therapeutics-may2026-deepdive/
0 · Reply
draketdot
draketdot Apr. 30 at 10:19 PM
$SYRE 33% increase incoming?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 30 at 7:49 PM
$SYRE RSI: 77.96, MACD: 6.7487 Vol: 9.71, MA20: 64.26, MA50: 51.55 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FennickTradings
FennickTradings Apr. 30 at 1:19 PM
$SYRE enough cash for cvr dividend payout😅
0 · Reply
RunnerSignals
RunnerSignals Apr. 29 at 8:10 PM
market warriors $TENB $HUM $CHGG $BIIB $SYRE reversed from red to strong green closes with 6–12% intraday swings and volume 1.2x–1.6x avg
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Apr. 29 at 2:39 PM
$SYRE
1 · Reply
Latest News on SYRE
Spyre Therapeutics price target raised to $102 from $86 at Deutsche Bank

2026-05-12T14:50:09.000Z - 1 day ago

Spyre Therapeutics price target raised to $102 from $86 at Deutsche Bank

Spyre Therapeutics price target raised to $97 from $64 at Citi

2026-05-07T08:43:33.000Z - 6 days ago

Spyre Therapeutics price target raised to $97 from $64 at Citi

Spyre Therapeutics price target raised to $107 from $92 at Stifel

2026-05-07T07:55:33.000Z - 6 days ago

Spyre Therapeutics price target raised to $107 from $92 at Stifel

Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)

2026-05-05T12:27:39.000Z - 8 days ago

Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026, 8:00 AM EDT - 8 days ago

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Grants of Inducement Awards

May 1, 2026, 4:28 PM EDT - 11 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics price target raised to $95 from $64 at JonesResearch

2026-04-17T09:05:40.000Z - 26 days ago

Spyre Therapeutics price target raised to $95 from $64 at JonesResearch

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

Apr 16, 2026, 4:15 PM EDT - 26 days ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

Spyre Therapeutics 6.5M share Secondary priced at $62.00

2026-04-15T09:50:13.000Z - 4 weeks ago

Spyre Therapeutics 6.5M share Secondary priced at $62.00

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

Apr 14, 2026, 10:38 PM EDT - 4 weeks ago

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

Spyre Therapeutics price target raised to $90 from $65 at Baird

2026-04-14T11:44:26.000Z - 4 weeks ago

Spyre Therapeutics price target raised to $90 from $65 at Baird

Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo

2026-04-14T10:30:34.000Z - 4 weeks ago

Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo

Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank

2026-04-14T08:40:36.000Z - 4 weeks ago

Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank

Spyre Therapeutics announces $300M offering of common stock

2026-04-13T20:50:45.000Z - 4 weeks ago

Spyre Therapeutics announces $300M offering of common stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Apr 13, 2026, 4:46 PM EDT - 4 weeks ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Spyre Therapeutics initiated with a Strong Buy at Raymond James

2026-04-13T20:12:35.000Z - 4 weeks ago

Spyre Therapeutics initiated with a Strong Buy at Raymond James

Spyre Therapeutics price target raised to $80 from $65 at Wedbush

2026-04-13T18:55:50.000Z - 4 weeks ago

Spyre Therapeutics price target raised to $80 from $65 at Wedbush

TAK

Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen

2026-04-13T18:55:10.000Z - 4 weeks ago

Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen

Spyre Therapeutics price target raised to $106 from $49 at Leerink

2026-04-13T18:45:43.000Z - 4 weeks ago

Spyre Therapeutics price target raised to $106 from $49 at Leerink

Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data

2026-04-13T18:36:05.000Z - 4 weeks ago

Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data

Leerink sees Spyre’s SPY001 Phase 2 Data as incrementally positive for Oruka

2026-04-13T18:35:24.000Z - 4 weeks ago

Leerink sees Spyre’s SPY001 Phase 2 Data as incrementally positive for Oruka

ORKA

Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data

2026-04-13T18:30:13.000Z - 4 weeks ago

Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data

Spyre Therapeutics price target raised to $98 from $70 at BTIG

2026-04-13T18:26:20.000Z - 4 weeks ago

Spyre Therapeutics price target raised to $98 from $70 at BTIG

Spyre Therapeutics Transcript: Study result

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

Spyre Therapeutics Transcript: Study result

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Apr 13, 2026, 7:00 AM EDT - 4 weeks ago

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

Apr 10, 2026, 4:05 PM EDT - 4 weeks ago

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

Spyre Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:40 AM EDT - 2 months ago

Spyre Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Spyre Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 3:10 PM EST - 2 months ago

Spyre Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 4:05 PM EST - 2 months ago

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 19, 2026, 4:02 PM EST - 2 months ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Jan 12, 2026, 8:00 AM EST - 4 months ago

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Spyre Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 7:55 AM EST - 5 months ago

Spyre Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Spyre Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:00 AM EST - 6 months ago

Spyre Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Spyre Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:40 AM EST - 6 months ago

Spyre Therapeutics Transcript: Stifel 2025 Healthcare Conference

Spyre Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 10:00 AM EST - 6 months ago

Spyre Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:05 PM EST - 6 months ago

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Nov 4, 2025, 4:01 PM EST - 6 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Oct 24, 2025, 8:00 AM EDT - 7 months ago

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Oct 15, 2025, 4:15 PM EDT - 7 months ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Oct 13, 2025, 9:07 PM EDT - 7 months ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Oct 13, 2025, 4:01 PM EDT - 7 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Oct 5, 2025, 9:00 AM EDT - 7 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Spyre Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 15, 2025, 10:00 AM EDT - 8 months ago

Spyre Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 4:02 PM EDT - 10 months ago

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Transcript: Status Update

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Spyre Therapeutics Transcript: Status Update

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Jun 17, 2025, 7:30 AM EDT - 11 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Jun 16, 2025, 4:05 PM EDT - 11 months ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Spyre Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 9:20 AM EDT - 1 year ago

Spyre Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Spyre Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Spyre Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 28, 2025, 8:30 AM EDT - 1 year ago

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

May 5, 2025, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Spyre Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 3:10 PM EST - 1 year ago

Spyre Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Feb 19, 2025, 8:00 AM EST - 1 year ago

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Jan 13, 2025, 8:00 AM EST - 1 year ago

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Dec 18, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Spyre Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 7:30 AM EST - 1 year ago

Spyre Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Dec 2, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 5:11 PM EST - 1 year ago

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Spyre Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 5:30 AM EST - 1 year ago

Spyre Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Nov 18, 2024, 9:18 PM EST - 1 year ago

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

oaksapollo
oaksapollo May. 12 at 3:46 AM
$SYRE this is the most absurd valuation in biotech right now. Anyone can use YTE and do what they’re doing.
1 · Reply
chking09
chking09 May. 11 at 5:28 PM
$SYRE breakout?
0 · Reply
Quantumup
Quantumup May. 6 at 11:12 AM
Stifel y'day⬆️ $SYRE's PT to $107 (was $92), reit'd at Buy/said: Following best-in-class UC PoC data for SPY001 (α4β7), SYRE is well-positioned heading into additional PoC cohorts for SPY002 (TL1A) and SPY003 (IL-23p19) in mid-year/3Q26. $JNJ TAK APGE ABVX $ABBV Here's what else Stifel had to say: https://x.com/Quantumup1/status/2051982840607215753?s=20
0 · Reply
d_risk
d_risk May. 5 at 2:55 PM
$SYRE - Spyre Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +208.0% above peer average (36,855 vs 11,964 across 652 peers). SYRE’s 10-Q sharpens its downside: survival now explicitly hinges on new capital despite a large cash balance; it doubles down on going-concern, perpetual-loss, and no-revenue risks; concentrates dependence on four core programs and complex drug/device, biologics and CMC hurdles; and materially expands regulatory, IP, manufacturing, AI, talent, pricing, geopolitical and control‑weakness risks that could dilute shareholders, delay approvals and cripple commercialization. 🟢 Added 🟠 Removed https://d-risk.ai/SYRE/10-Q/2026-05-05
0 · Reply
Merlintrader
Merlintrader Apr. 30 at 11:10 PM
$SYRE Spyre Therapeutics 2026 (Nasdaq: $SYRE): When Great Clinical Data Matter More Than Promises https://www.merlintrader.com/spyre-therapeutics-may2026-deepdive/
0 · Reply
draketdot
draketdot Apr. 30 at 10:19 PM
$SYRE 33% increase incoming?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 30 at 7:49 PM
$SYRE RSI: 77.96, MACD: 6.7487 Vol: 9.71, MA20: 64.26, MA50: 51.55 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FennickTradings
FennickTradings Apr. 30 at 1:19 PM
$SYRE enough cash for cvr dividend payout😅
0 · Reply
RunnerSignals
RunnerSignals Apr. 29 at 8:10 PM
market warriors $TENB $HUM $CHGG $BIIB $SYRE reversed from red to strong green closes with 6–12% intraday swings and volume 1.2x–1.6x avg
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Apr. 29 at 2:39 PM
$SYRE
1 · Reply
grandefappuccino
grandefappuccino Apr. 28 at 8:49 PM
$SYRE ready to run 5/5
0 · Reply
Avocado_smash
Avocado_smash Apr. 28 at 2:43 AM
$SYRE Structure and Trend strength up>
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Apr. 24 at 2:18 PM
$SYRE 68.8 is your friend.
2 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Apr. 23 at 6:50 PM
$SYRE Trim under 70
1 · Reply
Avocado_smash
Avocado_smash Apr. 15 at 1:11 PM
$SYRE Strong Offering! 🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
Pika_Capital
Pika_Capital Apr. 15 at 1:10 PM
$SYRE $400M raised at $62. Power move. They got tons of cash now
0 · Reply
DonCorleone77
DonCorleone77 Apr. 15 at 10:30 AM
$SYRE Spyre Therapeutics 6.5M share Secondary priced at $62.00 The deal size was increased to $403M in common stock from $300M in common stock. Jefferies, Goldman Sachs, Evercore ISI and Guggenheim acted as joint book running managers for the offering.
0 · Reply
AlertsAndNews
AlertsAndNews Apr. 15 at 2:46 AM
$SYRE offering here Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock "today announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $62.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $403.0 million"
0 · Reply
Stocks_and_Stacks
Stocks_and_Stacks Apr. 14 at 4:14 AM
🚀 Bulls charging hard on April 13 amid renewed US-Iran peace talk hopes! 🐂📈 First off 😎 who’s all up late studying charts and getting ready for tomorrow? Our group just received two new banger alerts that have serious 100-200% run potential. Eyes sharp, bulls! Huge congrats to everyone riding these top 5 movers today – resilience and catalysts delivered big green! $RVMD +41% – Revolution Medicines soaring on positive new clinical trial results in oncology. $XNDU +28% – Xanadu Quantum Technologies lifting on quantum computing buzz and sector momentum. $CAR +24% – Avis Budget Group jumping amid strong rental demand and sector rotation. $SYRE +23% – Spyre Therapeutics climbing on biotech pipeline momentum. $RCT +90%+ (earlier surge) – RedCloud Holdings exploding on a major $30M Saudi licensing deal for its RAID engine. Epic day stacking wins despite the headlines, bulls… 💪 Who else is celebrating big gains? Drop your winners below. #TopMovers #BullMarket #Stocks #BangerAlerts
0 · Reply
deweyeggbert
deweyeggbert Apr. 14 at 1:47 AM
$SYRE big dilution dip coming. Institutions will use that dip to acquire shares on the cheap. I'm in with puts and maybe go long when the dust settles.
1 · Reply
mikesterz7
mikesterz7 Apr. 14 at 1:18 AM
$SYRE Spyre is looking forward to developing the drug as a single treatment, as well as in combination with its investigational antibodies SPY002 or SPY003.
0 · Reply